Nikhil C. Munshi, MD, on Multiple Myeloma: Idecabtagene Vicleucel in Patients With Relapsed or Refractory Disease
ASCO20 Virtual Scientific Program
Nikhil C. Munshi, MD, of Dana-Farber Cancer Institute, discusses initial results from the KarMMa tria, showing that idecabtagene vicleucel, a B-cell maturation antigen-targeted CAR T-cell therapy, demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma. Efficacy and safety data support a favorable clinical benefit-risk profile across the target dose range (Abstract 8503).
The ASCO Post Staff
Parameswaran Hari, MD, of the Medical College of Wisconsin, discusses phase III data from a 6-year follow-up of the STaMINA trial, which compared progression-free survival among 758 patients with high-risk multiple myeloma who received a second autologous transplant and lenalidomide maintenance; consolidation with lenalidomide, bortezomib, and dexamethasone followed by lenalidomide maintenance; or lenalidomide maintenance alone (Abstract 8506).
The ASCO Post Staff
David C. Fajgenbaum, MD, MBA, of the University of Pennsylvania, who trained as an oncologist, summarizes his opening lecture, a dramatic story of his battle against Castleman, a disease of the lymph nodes, his multiple near-death experiences, and the path that led him to develop a cooperative research effort making a difference for him and other patients with this idiopathic orphan illness.
The ASCO Post Staff
Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses data from a phase II study of pevonedistat plus azacitidine vs azacitidine alone in patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or low-blast acute myeloid leukemia (Abstract 7506).
The ASCO Post Staff
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses three important studies focusing on newer therapies for patients with recurrent platinum-sensitive, platinum-agnostic, and advanced recurrent ovarian cancers (Abstracts 6003, 6004, and 6005).
The ASCO Post Staff
Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses data from the ADAURA study, which showed that compared with placebo, osimertinib as adjuvant therapy after complete tumor resection reduced the risk of disease recurrence or death by 79% in patients with non–small cell lung cancer (Abstract LBA5).